Volume : 08, Issue : 04, April – 2021
Title:
44.UPDATED REVIEW OF COMMUNITY-ACQUIRED PNEUMONIA AMONG GENERAL POPULATION
Authors :
Waleed Mohammed Omar Almahaili, Faiasal Hamad Alzaidi , Abdualrhman Mohammed Alshamrani , Seraj Ali Alshareef , Mohammed awwad alhemmyni , Essam Musaed Alomairi , Saeed Utman Alghamdi , Mohammed Yahya Alamer ,
Abdullah Hamoud Aldahhasi , Khaled Mohammed Alhazmi
Abstract :
Community-acquired pneumonia (CAP) is the most prevalent contagious illness cause of death. We summarize newly released findings regarding the etiology of CAP in adults, efficiency of injections versus Streptococcus pneumoniae, diagnostics, and review the current therapy options. We searched for eligible articles as of June 2021 through PubMed, and Embase. We have used the following search MeSh terms for PubMed: (community acquired pneumonia), Treatment and diagnosis CAP is a significant cause of infectious illness mortality, with an increasing prevalence with age. With an aging population, CAP will undoubtedly remain a worldwide problem. Although Streptococcus pneumoniae is still the most commonly isolated infection in CAP, the relative incidence of other pathogens has increased. Comorbidities and other risk factors should trigger medical suspicion. Advances in immunization, such as the introduction of PCV and subsequent herd resistance, as well as the potential use of PCV in adults, should help minimize the amount of sickness caused by S. pneumoniae.
Cite This Article:
Please cite this article in press Waleed Mohammed Omar Almahaili et al., Updated Review Of Community-Acquired Pneumonia Among General Population.., Indo Am. J. P. Sci, 2021; 08(04).
Number of Downloads : 10
References:
1. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: iii1–iii55.
2. Froes F, Diniz A, Mesquita M, et al. Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009. Eur Respir J 2013; 41:1141–1146.
3. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752–761.
4. Gao H-N, Lu H-Z, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277–2285.
5. Yi L, Guan D, Kang M, et al. Family clusters of avian influenza A H7N9 infection in Guangdong province, China. J Clin Microbiol 2015; 53:22–28.
6. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155–163.
7. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal noninvasive community-acquired pneumonia. Thorax 2012; 67:540–545.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27–S72.
9. Beovic B, Bonac B, Kese D, Avsic-Zupanc T, Kreft S, Lesnicar G, et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 2003;22:584–91.
10. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.
11. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405–33.
12. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Pharmacotherapy. 2001;21(pt 2):S89–94.
13. Priebe DL, Chambliss ML. Blood cultures not helpful for community-acquired pneumonia. J Fam Pract. 2003;52:599–600.
14. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest. 2003;123:1142–50.
15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.
16. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997;157:36–44.
17. Fine MJ, Pratt HM, Obrosky DS, Lave JR, McIntosh LJ, Singer DE, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med. 2000;109:378–85.
18. Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, et al. for the Hopkins CAP team. Implications for macrolide treatment in community-acquired pneumonia. Chest. 1998;113:1201–6.
19. Mandell LA. Antibiotics for pneumonia therapy. Med Clin North Am. 1994;78:997–1014.
20. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. for the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383–421.
21. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Working Group. Arch Intern Med. 2000;160:1399–408.
22. Mandell LA, Bergeron MC, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis. 1995;6:306
23. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics. 2002;20:513–28.